Biotechnology

Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal...

Goldman Sachs has initiated coverage on Micromet (NASDAQ: MITI) with a Neutral rating and $5 price target.

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application for the treatment of neovascular age-...

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that results from two pivotal KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with refractory chronic gout have been published in The Journal of the American Medical Association. The data demonstrated that treatment with...

Nymox Pharmaceutical Corporation (Nasdaq: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Rancho...

Carbonite (NASDAQ: CARB) +18.51% on heavy volume. Peregrine Pharmaceuticals (NASDAQ: PPHM) +10.95% on heavy volume. Majesco Entertainment (NASDAQ: COOL) +12.31% on heavy volume

Shares of Marshall Edwards (NASDAQ: MSHL) are screaming higher this morning on word that its Investigational New Drug application for ME-143, the Company's lead NADH oxidase inhibitor, has been approved by the FDA. Currently, shares are higher by 52.90%, trading at $2.11. Shares of Novogen Limited...

Zacks is out with its report today on EpiCept (NASDAQ: EPCT), maintaining Outperform. In its report, Zacks writes, "The Company s lead cancer candidate Ceplene has been already approved in EU and Israel for the remission maintenance of AML and a pivotal trial is planned in the US. The Company s...

Marshall Edwards Inc (NASDAQ: MSHL) climbed 40.58% to $1.94 at 9:45 am. The US Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for ME-143. Pernix Therapeutics Holdings Inc (AMEX: PTX) shares advanced 36.64% to $8.95. PTX's net revenue surged...

Rodman & Renshaw has published a report on Inovio Pharmaceuticals (AMEX: INO), lowering the price target from $4 to $2. In the report, Rodman & Renshaw wrote, "Inovio recently reported data from a Phase 1 trial of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza...

MLV is out with its report today on Aastrom Biosciences (NASDAQ: ASTM), raising its PT to $7.50 from $5.50. In its report, MLV writes, "We have revised our model and project that Aastrom could become profitable in 2015 following the launch of ixmyelocel-T (assuming REVIVE produces positive results...

PharmAthene, Inc. (NYSE: PIP) announced today that the Company has been awarded a $5.7 million contract under a Department of Defense Broad Agency Announcement for studies directed at the development of an advanced expression system for the bioproduction of its nerve agent medical countermeasure...

Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that its Investigational New Drug application for ME-143 (formerly NV-143), the Company's lead NADH oxidase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The Company plans to initiate a Phase I clinical trial of...

Icagen, Inc. (Nasdaq: ICGN) announced today that it has mailed the following letter to stockholders reiterating its recommendation that Icagen stockholders accept the $6 per share tender offer by Pfizer Inc. (NYSE: PFE): August 16, 2011 Dear Icagen Stockholder: You should have recently received...

J.P. Morgan Chase & Co. is out with a research report on Gilead Sciences (NASDAQ: GILD) and is adding it to the Focus List. It has an Overweight rating and a $50 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We are adding Gilead to the J.P. Morgan Analyst...